Depralin ODT (Escitalopram) is relevant across therapeutic domains where additional symptomatic support is needed, assisting with managing symptoms that interfere with daily functioning.

The active ingredient's use is documented for specific indications, which include Major Depressive Episodes, Generalized Anxiety Disorder (GAD), Panic Disorder (with or without Agoraphobia), Social Anxiety Disorder (Social Phobia), and Obsessive-Compulsive Disorder (OCD).

The medication is relevant in clinical settings marked by temporary physiological imbalance, such as during episodes of pervasive low mood or heightened anxiety. It is commonly used to help with challenging manifestations like persistent loss of interest (anhedonia), excessive worry, and the episodic fear of panic attacks. This supportive relief contributes to easing the overall symptom load during periods of heightened symptoms and may assist patients with coping more steadily with difficult emotional episodes.

---

Quick Fact: Relief for Mood and Anxiety Symptoms

Depralin ODT is commonly used to help manage symptom clusters that may become intense or disruptive, such as persistent low mood and chronic, uncontrollable worry, assisting with maintaining functional stability.

Eligibility for Depralin ODT (Escitalopram)

Official regulatory guidelines define specific populations for whom Depralin ODT is approved, restricted, or contraindicated.

Absolute Contraindications

Use is contraindicated in patients who are currently taking a Monoamine Oxidase Inhibitor (MAOI), including linezolid or intravenous methylene blue, or within 14 days of discontinuing an MAOI. It is also prohibited for individuals with a known hypersensitivity to escitalopram, citalopram, or any ingredient in the formulation. Certain regulatory bodies also list known QT interval prolongation as a contraindication.

---

Age-Related Eligibility

Age Group	Eligibility Status (Regulatory Basis)
Adults (18+ years)	Eligible for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD).
Adolescents (12–17 years)	Eligible for MDD.
Children (7–11 years)	Eligible for GAD.
Children (<7 years)	Use not approved for GAD. Safety and effectiveness for MDD are not established below 12 years.
Geriatric (65+ years)	Eligible, but recommended maximum daily dose is 10 mg.

---

Conditional Use and Restrictions

Specific limitations exist for populations where the drug's clearance may be altered or where pre-existing conditions pose a risk, requiring special caution. These include patients with hepatic impairment, who are recommended a maximum daily dose of 10 mg. Caution is also advised for patients with a history of seizure disorders, mania, or severe renal impairment (creatinine clearance less than 20 mL/min). During pregnancy, use is limited to situations where the potential benefit justifies the risk, and caution is advised while breastfeeding as the drug is excreted into human milk.

Interactions with other medicines and products

Official regulatory documents define specific restrictions for co-administering Depralin ODT (Escitalopram) with certain drugs and substances. These constraints are based on the potential for altered plasma concentration (pharmacokinetic effects) or additive physiological effects (pharmacodynamic effects).

Prohibited Combinations

Co-administration with Depralin ODT is formally contraindicated by regulatory agencies in the following situations:

• Monoamine Oxidase Inhibitors (MAOIs): This includes non-selective, irreversible MAOIs, as well as agents like Linezolid and intravenous Methylene Blue. A mandatory 14-day separation period is required when switching between Depralin ODT and these MAOIs.
• Pimozide and other medicinal products known to prolong the QT interval, due to the risk of severe heart rhythm abnormalities.

Other Documented Interaction Risks

Interaction Type	Interacting Agents or Category	Regulatory Finding
Serotonergic	Triptans, Tramadol, Lithium, other SSRIs	Co-use may increase the risk of Serotonin Syndrome.
Metabolic	Omeprazole, Cimetidine (CYP2C19 inhibitors)	May increase Escitalopram plasma concentration.
Bleeding Risk	NSAIDs, Warfarin, Aspirin	Documented to increase the risk of abnormal bleeding.

Additionally, regulatory information advises against the use of alcohol and the herbal product St. John's Wort during treatment due to potential for increased adverse effects. An increased risk of hyponatremia is noted for elderly patients and those with hepatic impairment when co-administering with other medications that cause low sodium.

How Depralin ODT Works at the Biological Level

Depralin ODT (Escitalopram) acts by modulating the central serotonergic system to influence activity within the neural circuits governing emotion processing. Its primary mechanism is a targeted cascade beginning at the molecular level. The drug functions as a selective inhibitor of the Serotonin Transporter (SERT), a protein located on the presynaptic neuronal membrane.

By binding to SERT, the drug blocks the active reuptake of serotonin ( 5-HT) from the synaptic cleft, thereby increasing the concentration and duration of 5-HT signaling. This alteration of the 5-HT concentration gradient constitutes the immediate pharmacodynamic action.

Over the longer term, the sustained enhancement of synaptic serotonin drives adaptive changes in neuronal function, including the gradual desensitization and adjustment of postsynaptic 5-HT receptors. This slow, homeostatic modulation promotes the adjustment of neuronal signaling pathways, influencing the long-term functional pattern of central nervous system activity.

How to Use Depralin ODT

Depralin ODT is administered through the oral route using the specialized Oral Disintegrating Tablet (ODT) formulation. This administration method is designed to allow the tablet to dissolve directly on the tongue, enabling the dose to be swallowed with saliva, which means water is not required for intake. The medicine can be taken at any time of day, and administration is typically performed with or without food.

---

Official Dosing and Frequency

The established usage pattern for adults specifies taking the medication once daily. Treatment typically begins with a starting dose of 10 mg of Escitalopram. The standard therapeutic dosage is generally maintained at 10 mg/day, but it may be increased up to a maximum daily dose of 20 mg. Dose adjustments from 10 mg to 20 mg should only be undertaken no sooner than one week after the initiation of the initial regimen. Use often continues as part of a long-term plan for maintenance.

---

Population-Specific Use Limits

There are specific parameters for certain populations. For older adults (aged 65 years and over), the maximum recommended daily dose of Escitalopram is restricted to 10 mg. Patients diagnosed with hepatic impairment (reduced liver function) are typically started on a lower initial dose of 5 mg/day, with their maximum dose similarly limited to 10 mg/day. These specific instructions define the standardized use of the medicine across diverse patient contexts.

Research evidence / Overview of Studies for Depralin ODT

This overview summarizes the research regarding the clinical evaluation of Escitalopram, the active ingredient in Depralin ODT. This text focuses on the types of clinical studies conducted, the research outcomes they measured, and limitations documented in the scientific literature. The information presented here is derived from official regulatory and peer-reviewed sources and does not offer medical advice or treatment recommendations.

---

Evidence for Use in Major Depressive Episodes (MDD)

The research base for use in Major Depressive Episodes (MDD) rests on multiple Randomized Controlled Trials (RCTs). These short-term studies, typically lasting 6 to 8 weeks, were designed to assess outcomes in Escitalopram-treated groups versus groups receiving an inactive substance (placebo). Researchers also conducted meta-analyses to synthesize data. The outcomes measured focused on changes in standardized Depression Rating Scale Scores and the percentage of patients meeting criteria for remission status. Long-term studies monitored patterns related to the occurrence of relapse or recurrence in populations that had reached a specific status. Research documentation highlights that the data requires periodic review to characterize the status of ongoing use, as long-term effects are not fully established.

---

Evidence for Use in Anxiety and Related Disorders

Research has examined Escitalopram for use in various anxiety and related conditions. For Generalized Anxiety Disorder (GAD), the evidence comes from multiple short-term RCTs and subsequent pooled analyses, which examined outcomes related to Anxiety Rating Scale Scores and patient-reported changes in Quality of Life. Studies monitored adult populations, with some research also including children and adolescents. Evidence remains limited and heterogeneous concerning systematic characterization of the duration of the effect beyond the initial 8 weeks in all acute GAD populations.

Research Summary for Obsessive-Compulsive Disorder (OCD)

The evidence base for Obsessive-Compulsive Disorder (OCD) includes intermediate-term Placebo-controlled Trials and Systematic Reviews. Studies explored changes measured by specialized assessments, such as the Obsessive-Compulsive Scale (YBOCS). Longer studies monitored patterns in the occurrence of relapse for up to 6 months. A key limitation is the limited comparative evidence against non-SSRI treatments in some study contexts. Research focusing specifically on the Oral Disintegrating Tablet (ODT) formulation is limited; the core evidence base is established on the Escitalopram active ingredient.

Key Studies & References

1. Escitalopram Oral: U.S. National Library of Medicine Drug Information (MedlinePlus)

Common questions about Depralin ODT (FAQ)

Q: How long does it typically take for Depralin ODT to start working?

According to studies of the active ingredient, the time required to reach a stable concentration in the bloodstream, known as steady-state concentration, is typically around one week (7 to 10 days) of daily use. This achievement of a stable concentration is a necessary precondition, but the observable clinical effect can vary among individuals.

Q: Is Depralin ODT the same as Escitalopram?

Depralin ODT is a brand name medication for a specialized Oral Disintegrating Tablet formulation. Its sole active ingredient is escitalopram. Therefore, the medicine contains escitalopram, but the brand refers to the specific product and formulation.

Q: Is Depralin ODT considered a strong medicine?

Official documents describe the active ingredient as a highly selective serotonin reuptake inhibitor (SSRI). This chemical description means it primarily targets the serotonin system with minimal effects on other neurotransmitter systems, distinguishing its profile within its class.

Q: Is weight gain a potential side effect listed for Depralin ODT?

Official labeling states that decreased appetite is a common side effect. Although clinical research has examined general weight change for the active ingredient, studies have documented only small differences in mean weight compared to other medications in its class.

Q: What happens if a dose of Depralin ODT is missed?

Official guidance documents address situations where a dose is forgotten. The usual recommendation involves considering the time elapsed since the missed dose and the proximity to the next scheduled dose, with the goal of avoiding a double dose.

Q: Is Depralin ODT a controlled substance in the US?

Official regulatory sources, such as the U.S. Drug Enforcement Administration (DEA), do not classify escitalopram, the active ingredient in Depralin ODT, as a federally controlled substance. This indicates it is not considered addictive in the manner of controlled substances.

Q: How does the 'ODT' formulation change the onset of action compared to a regular tablet?

Information on how the Oral Disintegrating Tablet (ODT) formulation changes the time of onset compared to a regular tablet is not detailed in the core regulatory documents. The ODT feature simplifies administration by dissolving on the tongue.

Q: Can Depralin ODT affect driving or operating machinery?

Regulatory product information notes that the medicine may interfere with cognitive and motor performance, and therefore advises caution regarding operating machinery or driving a motor vehicle.

Q: Is it true that Depralin ODT is also used for panic disorder?

While the U.S. regulatory agency approved the active ingredient for Major Depressive Disorder and Generalized Anxiety Disorder, official product information in European countries also lists the active ingredient as approved for the treatment of Panic Disorder.

Q: Is Depralin ODT considered habit-forming?

The active ingredient is not classified as a controlled substance, indicating it is not considered addictive in the same way as controlled substances. However, physical dependence can develop with long-term use, meaning that stopping the medication suddenly can lead to discontinuation symptoms.

Q: Can Depralin ODT change blood pressure?

Regulatory warnings indicate that the medication may interact with certain prohibited drugs, which can, in rare cases, lead to a serious reaction. This reaction includes a risk of extremely high blood pressure when co-administered with specific prohibited medications.

Q: What is the purpose of the scored line on some Depralin ODT tablets?

Official labeling for the active ingredient's tablets indicates that the 10 mg and 20 mg strengths are scored, while the 5 mg strength is not. The scored line's designated function is to facilitate the division of the tablet for dosage adjustment when a partial dose is required.

Q: Is it normal to feel a change in mood soon after starting Depralin ODT?

Official warnings state that antidepressants may cause a change in mood or behavior at the start of therapy, including clinical worsening and the emergence of suicidal thoughts or behaviors. Regulatory documents require that patients be closely monitored, particularly when first starting therapy or changing the dose.

Q: What is the difference between Depralin ODT and citalopram?

The active ingredient, escitalopram, is officially described as the highly active S-enantiomer of racemic citalopram. This chemical distinction differentiates it from its predecessor and is the basis for its highly selective action.

Q: What does the term 'side effect profile' mean for Depralin ODT?

The term, used in official documentation, refers to the summary of all documented adverse reactions (side effects). This summary organizes the effects observed in clinical trials and post-marketing experience, categorized by how frequently they were reported.

Q: Are there specific organs that Depralin ODT can affect, according to official documents?

Warnings and precautions address use in patients with pre-existing conditions involving the liver (hepatic impairment) and the kidneys (renal impairment). Official information also addresses the risk of affecting the electrical activity of the heart (QT prolongation risk).

Q: What is the difference between Depralin ODT and other SSRIs, based on official information?

The active ingredient is chemically described as a highly selective inhibitor of the serotonin reuptake pump. This high selectivity, with minimal action on other systems, is cited as the key distinguishing characteristic of the medication within the SSRI class.

Q: Is there official information regarding the long-term mental side effects of Depralin ODT?

Regulatory documents include a Warnings and Precautions section that addresses certain mental health risks that may occur over the course of treatment. These warnings discuss the potential for the emergence of suicidal thoughts or actions and the activation of mania/hypomania.

How to Store and Dispose of Depralin ODT?

The storage and disposal of Depralin ODT (Escitalopram Oral Disintegrating Tablet) are governed by specific regulatory guidelines to ensure the medicine's stability and safe management.

Official Storage Requirements

Storage Scope	Labeled Requirement
Temperature	Store at or below 30 C (Controlled Room Temperature).
Protection	Keep in the original package to protect from light and moisture.
Handling	Do not touch the tablets with wet hands as the ODT formulation dissolves quickly.
Child Safety	Keep out of the sight and reach of children.

Disposal Requirements

The product must not be used after the expiry date (EXP). Official instructions prohibit disposing of the unused medicine into wastewater or household waste. Unused or expired medication must be returned to a pharmacy or disposed of according to local requirements for proper environmental management.